Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Effects of Unilateral and Bilateral Transcutaneous Auricular Vagus Nerve Stimulation on Voice Acoustics in Healthy Adults (taVNS-VOICE)

9 listopada 2026 zaktualizowane przez: SEFA HAKTAN HATIK, Sinop University

Acute Effects of Unilateral and Bilateral Transcutaneous Auricular Vagus Nerve Stimulation on Acoustic Voice Parameters and Autonomic Function in Healthy Adults: A Randomized, Sham-Controlled, Three-Period Crossover Trial

This study aims to investigate the immediate effects of transcutaneous auricular vagus nerve stimulation (taVNS) on voice characteristics and autonomic function in healthy adults.

A total of 36 healthy adults aged 18-30 years will participate in this randomized, sham-controlled, three-period crossover trial. Each participant will receive three interventions in a randomized order: unilateral active taVNS, bilateral active taVNS, and sham stimulation. Each intervention will last 20 minutes, with at least seven days between visits.

Voice characteristics will be evaluated before and after each intervention using acoustic analysis. The primary outcome will be shimmer, a measure of variation in voice amplitude. Secondary outcomes will include jitter, harmonics-to-noise ratio, and fundamental frequency. Perceived vocal effort, heart rate, and pulse rate variability will also be assessed.

The study will compare the immediate effects of unilateral, bilateral, and sham stimulation on voice stability and explore possible relationships between voice changes and autonomic responses.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

This prospective, randomized, sham-controlled, three-period crossover trial will investigate the acute effects of unilateral and bilateral transcutaneous auricular vagus nerve stimulation (taVNS) on acoustic voice parameters and autonomic function in healthy adults.

Thirty-six participants aged 18-30 years will be allocated to one of six intervention sequences (ABC, ACB, BAC, BCA, CAB, or CBA). Each participant will complete three intervention visits separated by a washout period of at least seven days.

The intervention conditions will include: (A) unilateral active stimulation of the left cymba conchae, (B) bilateral active stimulation of the cymba conchae, and (C) bilateral sham stimulation applied to the earlobes with an initial brief sensory stimulation followed by gradual reduction of current to zero. Stimulation will be delivered using Nurosym devices at 20 Hz and 200 μs for 20 minutes. Active stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Acoustic voice assessment will involve three recordings of sustained /a/ phonation before and after each intervention. Recordings will be analyzed using Praat software. Shimmer (%) will be the primary outcome, while jitter (%), harmonics-to-noise ratio (dB), and fundamental frequency (Hz) will be secondary outcomes.

Perceived vocal effort will be assessed using a 100-mm visual analogue scale. Autonomic responses will be evaluated using pulse rate variability measurements obtained with the Polar Verity Sense device, including RMSSD, SDNN, and mean heart rate.

Primary analyses will use linear mixed-effects models to compare changes across intervention conditions while accounting for repeated measurements and study periods. Adverse events and stimulation tolerability will be monitored throughout the study.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

36

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

  • Nazwa: Sefa Haktan Hatık Principal Investigator, PhD, MSc, Physiotherapist
  • Numer telefonu: +90 505 876 1553
  • E-mail: haktanhtk@gmail.com

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 30 lat (Dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Adults aged 18-30 years.
  • Self-reported good general health without known systemic diseases preventing safe participation.
  • Native Turkish speakers.
  • No current hoarseness, vocal strain, or known laryngeal/voice disorders.
  • No current use of cigarettes, electronic cigarettes, heated tobacco, or other nicotine products.
  • Ability and willingness to attend three intervention visits separated by at least 7 days.
  • Ability to understand and follow study procedures.
  • Provision of written informed consent.

Exclusion Criteria:

  • Known cardiovascular disease, clinically significant arrhythmia, uncontrolled hypertension or hypotension, or unexplained syncope.
  • History of epilepsy, seizures, or serious neurological disorders.
  • Known vocal fold or laryngeal pathology, chronic voice disorders, previous laryngeal surgery, or significant hoarseness.
  • Active respiratory infection, laryngitis, sore throat, or febrile illness.
  • Ear infections, wounds, dermatological lesions, hypersensitivity, or piercings interfering with electrode placement.
  • Pacemakers, implantable cardioverter-defibrillators, or other active electronic implants.
  • Pregnancy or suspected pregnancy.
  • Current tobacco or nicotine use.
  • Regular use of medications significantly affecting autonomic function or voice, including beta-blockers, antiarrhythmics, anticholinergics, sedatives, or psychoactive medications.
  • Failure to comply with pre-assessment restrictions concerning caffeine, alcohol, vigorous exercise, or vocal loading; visits may be rescheduled when possible.
  • Clinically significant intolerance or adverse reactions to stimulation requiring discontinuation.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Podstawowa nauka
  • Przydział: Randomizowane
  • Model interwencyjny: Zadanie krzyżowe
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Sequence ABC

Unilateral active taVNS, followed by bilateral active taVNS, then bilateral sham stimulation. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Eksperymentalny: Sequence ACB

Unilateral active taVNS, followed by bilateral sham stimulation, then bilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Eksperymentalny: Sequence BAC

Bilateral active taVNS, followed by unilateral active taVNS, then bilateral sham stimulation. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Eksperymentalny: Sequence BCA

Bilateral active taVNS, followed by bilateral sham stimulation, then unilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Eksperymentalny: Sequence CAB

Bilateral sham stimulation, followed by unilateral active taVNS, then bilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Eksperymentalny: Sequence CBA

Bilateral sham stimulation, followed by bilateral active taVNS, then unilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits.

Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.

Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in Shimmer (%)
Ramy czasowe: At each of three visits: before intervention and after the 20-minute intervention and 5-minute PRV recording; visits separated by at least 7 days.

Shimmer (%) will be measured using Praat software from three sustained /a/ phonations. The stable middle 3-second segment of each recording will be analyzed, and the mean of three measurements will be used. Change will be calculated as post-intervention minus baseline shimmer.

At each of three visits: before intervention and after the 20-minute intervention and 5-minute PRV recording; visits separated by at least 7 days.
Change in Jitter (%)
Ramy czasowe: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

Change in cycle-to-cycle fundamental frequency variation, measured using Praat software from three sustained /a/ phonations.

At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in Harmonics-to-Noise Ratio (dB)
Ramy czasowe: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

Change in voice harmonic-to-noise ratio, measured using Praat software from three sustained /a/ phonations.

At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in Fundamental Frequency (Hz)
Ramy czasowe: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

Change in mean fundamental frequency (F0), measured using Praat software from three sustained /a/ phonations.

At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in Perceived Vocal Effort (mm)
Ramy czasowe: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.

Change in perceived vocal effort assessed using a 100-mm visual analogue scale (VAS), where higher scores indicate greater perceived vocal effort.

At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
Change in RMSSD (ms)
Ramy czasowe: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

Change in the root mean square of successive differences (RMSSD), calculated from 5-minute pulse rate variability recordings using Polar Verity Sense.

At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
Change in SDNN (ms)
Ramy czasowe: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

Change in the standard deviation of normal-to-normal pulse intervals (SDNN), calculated from 5-minute pulse rate variability recordings using Polar Verity Sense.

At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
hange in Mean Heart Rate (bpm)
Ramy czasowe: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

Change in mean heart rate measured using Polar Verity Sense during 5-minute recordings.

At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
Change in LF/HF Ratio
Ramy czasowe: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

Exploratory analysis of the low-frequency to high-frequency power ratio derived from pulse rate variability recordings.

At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

16 listopada 2026

Zakończenie podstawowe (Szacowany)

15 stycznia 2027

Ukończenie studiów (Szacowany)

31 stycznia 2027

Daty rejestracji na studia

Pierwszy przesłany

9 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 listopada 2026

Pierwszy wysłany (Rzeczywisty)

16 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

9 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • TAVNS-VOICE-CO-2026-01

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Individual participant data will not be shared with external researchers to protect participant confidentiality and privacy. Study findings will be reported in aggregate form in scientific publications.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .